scholarly journals Radiofrequency Ablation of Papillary Thyroid Microcarcinoma: A 10-Year Follow-Up Study

2021 ◽  
Vol 82 ◽  
Author(s):  
Yoo Kyeong Seo ◽  
Seong Whi Cho ◽  
Jung Suk Sim ◽  
Go Eun Yang ◽  
Woojin Cho
Keyword(s):  
Radiofrequency Ablation ◽  
Papillary Thyroid Microcarcinoma ◽  
Papillary Thyroid ◽  
Follow Up Study ◽  
Thyroid Microcarcinoma

scholarly journals Evaluation of Ultrasound-Guided Radiofrequency Ablation as a Treatment Option for Papillary Thyroid Microcarcinoma in the Isthmus: A Retrospective Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Qing Song ◽  
Hanjing Gao ◽  
Xiaoqi Tian ◽  
Ling Ren ◽  
Yu Lan ◽  
...  
Keyword(s):  
Lymph Node ◽  
Retrospective Study ◽  
Radiofrequency Ablation ◽  
Lymph Node Metastasis ◽  
Papillary Thyroid Microcarcinoma ◽  
Papillary Thyroid ◽  
Ultrasound Guided ◽  
Node Metastasis ◽  
Thyroid Microcarcinoma

BackgroundAbout 3–9.2% of papillary thyroid carcinomas (PTC) are found in the isthmus, which has unique anatomic properties, making treatment more challenging. The aim of this study was to evaluate the treatment and undesirable effects of ultrasound-guided radiofrequency ablation (RFA) for PTC in the isthmus.MethodsThis retrospective case series study assessed 112 patients with single papillary thyroid microcarcinoma in the isthmus, pathologically diagnosed before RFA at the General Hospital of Chinese PLA in 2014–2018. Follow-up was performed by contrast-enhanced ultrasound (CEUS) and ultrasound examinations at 1, 3, and 6 months and every 6 months thereafter. The complete ablation (CAR), disappearance (DR), and volume reduction (VRR) rates of nodules, the incidence of complications, and the rate of lymph-node metastasis were recorded.ResultsThe CAR of the tumors was 100%. During follow-up, the volume of coagulation necrosis gradually decreased. DRs at 1, 3, 6, 12, and 18 months after RFA were 0.8% (1/112), 10.7% (12/112), 51.7% (58/112), 91.0% (102/112), and 100% (112/112), respectively. The VRR evaluated by ultrasound and CEUS gradually increased. One recurrent case (0.8%) was found at 7 months after RFA. No complications, lymph node metastasis confirmed by ultrasound, and abnormal thyroid function were observed.ConclusionsThis retrospective study shows that RFA is beneficial for the treatment of PTMC in the isthmus.

Ultrasound-Guided Radiofrequency Ablation Versus Surgery for Low-Risk Papillary Thyroid Microcarcinoma: Results of Over 5 Years' Follow-Up

Thyroid ◽  
2020 ◽  
Vol 30 (3) ◽  
pp. 408-417 ◽  
Author(s):  
Mingbo Zhang ◽  
Ralph P. Tufano ◽  
Jonathon O. Russell ◽  
Ying Zhang ◽  
Yan Zhang ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Low Risk ◽  
Papillary Thyroid Microcarcinoma ◽  
Papillary Thyroid ◽  
Ultrasound Guided ◽  
Thyroid Microcarcinoma

scholarly journals The Efficacy and Safety of Radiofrequency Ablation for Bilateral Papillary Thyroid Microcarcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Lin Yan ◽  
Mingbo Zhang ◽  
Qing Song ◽  
Jing Xiao ◽  
Ying Zhang ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Preoperative Evaluation ◽  
Clinical Results ◽  
Papillary Thyroid Microcarcinoma ◽  
Complete Disappearance ◽  
Papillary Thyroid ◽  
Promising Alternative ◽  
Thyroid Microcarcinoma ◽  
The Mean

ObjectiveTo investigate the long-term clinical results of radiofrequency ablation (RFA) for bilateral papillary thyroid microcarcinoma (PTMC).Materials and MethodsFrom October 2014 to February 2018, 47 patients (37 females, 10 males, mean age 43.39 ± 9.26 years) with 100 bilateral PTMC (mean volume 75.22 ± 73.87 mm3) treated by RFA were included in this retrospective study. Bilateral PTMC was defined as at least one tumor located in the contralateral lobe. Patients were followed up at 1, 3, 6, 12 months and every 6–12 months thereafter. Volume, volume reduction ratio (VRR) and local tumor recurrence were evaluated during the follow-up period.ResultsAfter a mean follow-up period of 47.77 ± 11.54 months, the mean volume of bilateral PTMC decreased from 75.22 ± 73.87 mm3 to 0.09 ± 0.44 mm3. The mean VRR was 99.94 ± 0.28% and the complete disappearance rate was 92.00%. During the follow-up, one patient (2.13%) developed lymph node metastasis and two patients (4.26%) had recurrent PTMC. All the recurrent lesions underwent additional RFA and two of them disappeared completely. No life-threatening or delayed complications occurred.ConclusionsWith sufficient preoperative evaluation, RFA might be a promising alternative for bilateral PTMC patients who were unsuitable for surgery or refused surgery.

US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study

2020 ◽  
Vol 105 (6) ◽  
pp. 1791-1800 ◽  
Author(s):  
Wen-Wen Yue ◽  
Lu Qi ◽  
Dan-Dan Wang ◽  
Shou-Jun Yu ◽  
Xi-Ju Wang ◽  
...  
Keyword(s):  
Prospective Study ◽  
Distant Metastasis ◽  
Microwave Ablation ◽  
Large Population ◽  
Low Risk ◽  
Papillary Thyroid Microcarcinoma ◽  
Function Evaluation ◽  
Papillary Thyroid ◽  
Thyroid Microcarcinoma

Abstract Background Papillary thyroid microcarcinoma (PTMC) has become a main cause of the extremely high incidence of thyroid carcinoma. This study aimed to evaluate the longer-term effectiveness of ultrasound (US)-guided microwave ablation (MWA) for treatment of low-risk PTMC with a large population. Methods This prospective study was approved by ethics committee of our institution. MWA was performed under US-guidance for 119 unifocal PTMC patients without clinically cervical or distant metastasis. The target ablation zone exceeded the tumor edge judged by contrast-enhanced US to avoid marginal residue and recurrence. US and thyroid function evaluation were followed at 1, 3, 6, and 12 months after treatment and every 6 to 12 months thereafter. Any adverse event associated with MWA was evaluated. Results The follow-up duration after MWA was 37.2 ± 20.9 months (range 12-101 months). Tumor volume decreased significantly from 1.87 ± 1.03 mL immediately after MWA to 0.01 ± 0.04 mL at the final evaluation (P < 0.001), with a mean volume reduction ratio of 99.4 ± 2.2% and 107 cases (93.9%) got complete remission. A patient was detected with cervical lymph node metastasis at 26-month follow-up and underwent 1 additional MWA treatment successfully. No distant metastasis was observed. All the acquired histological pathology results confirmed the absence of residual or recurrent tumor cells after MWA. No delayed complications associated with MWA were encountered for all patients. Conclusions Percutaneous MWA is technically feasible for complete PTMC destruction and showed well longer-term effectiveness; thus, it seems to be an effective nonsurgical therapy to complement the current recommendation for selected low-risk PTMC patients.

Sign in / Sign up

Export Citation Format

Share Document